Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
By Lewis KrauskopfNEW YORK, Oct 15 (Reuters) - Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the...
By Lewis KrauskopfNEW YORK, Oct 15 (Reuters) - Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the...